A second study found elevated TAMs in three Nb cohorts (including ~ 25% MYCN‐A cases) compared with neurofibromas and showed that conversion of Nb TAMs to the pro‐inflammatory M1 phenotype using a CSF1 receptor tyrosine kinase inhibitor (TKI) slows tumor growth in the tyrosine hydroxylase‐MYCN transgenic murine HR Nb model [7]. The gene discussed is MYCN; the disease is neoplasm.